Trial Profile
Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Fosaprepitant (Primary) ; Dexamethasone; Dexamethasone; Serotonin 3 receptor antagonists
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms SENRI
- 01 Feb 2021 Results of pooled analysis from SENRI and other two studies assessing whether treatment with the triplet antiemetic prophylaxis involving aprepitant, is more effective in controlling delayed CINV than prophylaxis with palonosetron and dexamethasone, published in the Cancer Science
- 21 Jan 2017 Results of subgroup analysis of SENRI trial (n=370) presented at the 2017 Gastrointestinal Cancers Symposium
- 04 Jul 2015 Results presented at the 17th World Congress on Gastrointestinal Cancer.